Articles From This Issue
By Melina I. Morkin, MD; Lana M. Rifkin, MD; and Caroline Baumal, MD
Cover Focus: Mystery Cases
A 19-year-old woman had experienced recurrent episodes of episcleritis in the left eye for more than 3 months despite a variety of treatment regimens, including topical an…
By Jonathan L. Prenner, MD, and Richard S. Kaiser, MD
Retina doctors spend their careers reading the works of successful ophthalmologists who publish in trade publications and peer reviewed journals; rarely do they spend t…
Supplements and Inserts
By CARL D. REGILLO, MD
One of the key components of successful and safe retina surgery is the ability to engage target tissue while causing minimal or no disruption of adjacent tissue. Whether dissecting hyaloid near the retina, peeling a membrane, or performing core vitrectomy, the surgeon must be ever mindful of tractional forces and how much stress the intraocular maneuvers are placing on the retina-vitreous interface.
By Charles C. Wykoff, MD, PhD, moderator; Caroline R. Baumal, MD; David Eichenbaum, MD; and Chirag P. Shah, MD, MPH
The prevalence of diabetes is growing globally; as such the number of people affected by vision-threatening diabetic retinopathy (DR) is likewise expected to continue to increase. Prevent Blindness America has estimated more than 7.6 million people in the United States have DR as a result of their systemic disorder.1
By FIRAS M. RAHHAL, MD
The majority of my cases are operated using 23-gauge instrumentation using valved cannulas whenever possible. While I do use some 25-gauge, I prefer to use the technology with which I am most comfortable. I am not necessarily resistant to change; however, I have been getting very good results with my particular setup for over a decade, and so it is difficult for me to justify modifying my approach.
ThromboGenics Announces Publication in Experimental Eye Research of Preclinical Data Supporting Therapeutic Potential of THR-317 in DR
ThromboGenics NV announced that preclinical data on its THR-317 have been published in Experimental Eye Research. ThromboGenics’ preclinical studies are designed to investigate inhibition of pla…
PanOptica announced that it has secured $11 million in a Series B financing to enable clinical advancement of PAN-90806, a small molecule anti-vascular endothelial growth factor (anti-VEGF) eye drop f…